A Phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Quinazolines

abstract

  • Erlotinib at a dose of 2000 mg administered weekly was tolerated well by these patients with advanced NSCLC. The 5% objective response rate did not reach the stated objective at the interim efficacy analysis, prompting the closure of the study.

publication date

  • September 2006

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.22088

PubMed ID

  • 16878326

Additional Document Info

start page

  • 1034

end page

  • 41

volume

  • 107

number

  • 5